📊 OCEA Key Takeaways
Is Ocean Biomedical, Inc. (OCEA) a Good Investment?
Ocean Biomedical exhibits extreme financial distress with negative stockholders' equity of -$92.4M, liabilities exceeding assets by 59x, and a liquidity crisis evidenced by a 0.06x current ratio against $800K in cash. The negative revenue of -$2.0M and operating cash burn of -$356.0K indicate either severe product returns/accounting issues or pre-revenue status incompatible with $94M in liabilities, creating an existential solvency risk with minimal cash runway.
Fundamentals signal acute financial distress: negative equity ($-92.4M), minimal cash ($0.8M), and a 0.06x current ratio alongside sustained losses and negative revenue indicate urgent dependence on external financing. While net loss and EPS improved YoY and capex needs appear low, margins are distorted by negative revenue and interest coverage is negative, pointing to high dilution or insolvency risk absent a rapid, material turnaround.
Why Buy Ocean Biomedical, Inc. Stock? OCEA Key Strengths
- Operates in pharmaceutical sector with inherent high-margin potential
- Maintains $800K in cash providing short-term runway
- Potential turnaround opportunity if viable pipeline assets exist
- YoY improvement in net loss and EPS
- Asset-light profile with minimal capex (FCF ≈ OCF)
- Operating loss smaller than net loss, suggesting non-operating items dominate
OCEA Stock Risks: Ocean Biomedical, Inc. Investment Risks
- Negative stockholders' equity indicating technical insolvency
- Negative revenue of -$2.0M suggesting major product returns or accounting irregularities
- Liquidity crisis with current ratio of 0.06x and liabilities $94M vs assets $1.6M
- Operating cash burn of -$356.0K with only $800K cash (2.2 month runway)
- No insider Form 4 filings in 90 days indicating lack of management confidence
- Severe accumulated losses of -$8.2M in latest period
- Severe liquidity shortfall (cash $0.8M, current ratio 0.06x)
- Large shareholder deficit and heavy liabilities imply dilution/insolvency risk
- Negative revenue and ROA (-520.9%) indicate weak, unsustainable operations
Key Metrics to Watch
- Quarterly cash balance and burn rate trend
- Revenue sign and trajectory (confirm if negative revenues persist)
- Debt restructuring announcements or refinancing activities
- Clinical trial progress or regulatory approvals if in pipeline stage
- Insider buying activity and management changes
- Cash & equivalents (liquidity runway)
- Operating cash flow (burn rate)
Ocean Biomedical, Inc. (OCEA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
OCEA Profit Margin, ROE & Profitability Analysis
OCEA vs Healthcare Sector: How Ocean Biomedical, Inc. Compares
How Ocean Biomedical, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Ocean Biomedical, Inc. Stock Overvalued? OCEA Valuation Analysis 2026
Based on fundamental analysis, Ocean Biomedical, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Ocean Biomedical, Inc. Balance Sheet: OCEA Debt, Cash & Liquidity
OCEA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Ocean Biomedical, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-4.35 indicates the company is currently unprofitable.
OCEA Revenue Growth, EPS Growth & YoY Performance
Ocean Biomedical, Inc. Dividends, Buybacks & Capital Allocation
OCEA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Ocean Biomedical, Inc. (CIK: 0001869974)
📋 Recent SEC Filings
❓ Frequently Asked Questions about OCEA
What is the AI rating for OCEA?
Ocean Biomedical, Inc. (OCEA) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 89% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are OCEA's key strengths?
Claude: Operates in pharmaceutical sector with inherent high-margin potential. Maintains $800K in cash providing short-term runway. ChatGPT: YoY improvement in net loss and EPS. Asset-light profile with minimal capex (FCF ≈ OCF).
What are the risks of investing in OCEA?
Claude: Negative stockholders' equity indicating technical insolvency. Negative revenue of -$2.0M suggesting major product returns or accounting irregularities. ChatGPT: Severe liquidity shortfall (cash $0.8M, current ratio 0.06x). Large shareholder deficit and heavy liabilities imply dilution/insolvency risk.
What is OCEA's revenue and growth?
Ocean Biomedical, Inc. reported revenue of $-2.0M.
Does OCEA pay dividends?
Ocean Biomedical, Inc. does not currently pay dividends.
Where can I find OCEA SEC filings?
Official SEC filings for Ocean Biomedical, Inc. (CIK: 0001869974) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is OCEA's EPS?
Ocean Biomedical, Inc. has a diluted EPS of $-0.09.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is OCEA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Ocean Biomedical, Inc. has a STRONG SELL rating with 89% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is OCEA stock overvalued or undervalued?
Valuation metrics for OCEA: ROE of N/A (sector avg: 15%), net margin of 402.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy OCEA stock in 2026?
Our dual AI analysis gives Ocean Biomedical, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is OCEA's free cash flow?
Ocean Biomedical, Inc.'s operating cash flow is $-356.0K, with capital expenditures of N/A. FCF margin is 17.4%.
How does OCEA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 402.7% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.06 (avg: 2).